Producer
Pfizer Inc. (Hospira / Hospital Products)
Pfizer Inc. (New York; NYSE: PFE; ~$58B revenue) acquired Hospira Inc. in 2015 for $17 billion — making Pfizer the world's largest injectable pharmaceutical manufacturer. Hospira's legacy US injectable opioid manufacturing sites (McPherson KS; Rocky Mount NC) produce fentanyl citrate injection, morphine sulfate injection, and hydromorphone HCl injection in vial and prefilled syringe formats for hospital anesthesia, ICU sedation, and pain management. Hospira had accumulated multiple FDA Warning Letters for sterile manufacturing GMP deficiencies prior to the Pfizer acquisition; Pfizer inherited these compliance issues along with Hospira's dominant market position. McPherson KS is a large-volume sterile fill-finish facility producing Schedule II controlled substance injectables under DEA quota. The Pfizer/Hospira combination created a single company responsible for a major fraction of US hospital injectable opioid supply across multiple molecules simultaneously.
1
Inputs supplied
1
Goods downstream
2
Facilities
0
Stories
What they make
1 input Pfizer Inc. (Hospira / Hospital Products) supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Pfizer Inc. (Hospira / Hospital Products) makes, pick one to see the full supply chain.
Where they make it
2 facilities
Pfizer McPherson KS Injectable Manufacturing (Hospira legacy) →
USKansas · manufacturing
Large sterile injectable manufacturing facility in McPherson KS; Hospira legacy site producing fentanyl citrate injection, morphine sulfate injection, and hydromorphone HCl injection under DEA Schedule II quota. McPherson is one of Pfizer's largest US hospital injectable volume sites. Hospira had multiple FDA Warning Letters at McPherson prior to Pfizer acquisition; Pfizer remediated. Produces vials and prefilled syringes for hospital anesthesia and ICU use.
Pfizer Rocky Mount NC Injectable Manufacturing (Hospira legacy) →
USNorth Carolina · manufacturing
Pfizer sterile injectable manufacturing facility in Rocky Mount NC; Hospira legacy site. Produces hospital injectable pharmaceuticals including anesthesia and pain management injectables. Rocky Mount is one of multiple US Pfizer/Hospira injectable sites serving hospital formulary supply. North Carolina hosts both Pfizer Rocky Mount and Fresenius Kabi Wilson — making NC a significant geographic concentration point for US hospital injectable opioid manufacturing.
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
Injectable Opioids & Controlled Substances
40%Anesthesia & ICU Injectables
35%Hospital Sterile Products (non-controlled)
25%
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Did you know2023
Pfizer's McPherson, Kansas facility manufactures both oncology chemotherapy injectables (cisplatin, carboplatin) AND controlled substance injectables (fentanyl, hydromorphone, morphine) from the same GMP manufacturing site. A single quality incident or natural disaster (McPherson is in tornado alley) simultaneously affects the oncology drug supply chain AND the controlled substance hospital drug supply chain AND the anesthesia drug supply chain — three separate clinical areas depending on one Kansas manufacturing site. The 2022-2023 sterile injectable shortages that created US cisplatin supply crises also tightened fentanyl and morphine availability at some hospitals, demonstrating how shared manufacturing concentration propagates across multiple drug categories at once.
ASHP ↗Concentration2015
Pfizer's 2015 acquisition of Hospira for $17 billion created the world's largest injectable pharmaceutical manufacturer — but also concentrated a major fraction of US injectable opioid supply under a single corporate entity simultaneously managing quality remediation at multiple facilities. Hospira had accumulated FDA Warning Letters at multiple US manufacturing sites (McPherson KS, Rocky Mount NC, Clayton NC) for sterile manufacturing GMP deficiencies before the Pfizer acquisition. Pfizer inherited these quality issues along with Hospira's dominant market position. The consolidation meant that a quality failure, manufacturing disruption, or corporate financial crisis at a single company (Pfizer) could simultaneously disrupt supply of fentanyl citrate, morphine sulfate, and hydromorphone injection — the three most clinically important injectable opioids — from what had been previously independent competing manufacturers. The injectable pharmaceutical industry's tendency toward consolidation (Pfizer-Hospira being the largest example) reduces manufacturing redundancy precisely in the product categories where redundancy is most critical for public health.
Pfizer Inc. ↗Origin2015
Pfizer's hospital injectable operations are concentrated at Hospira legacy manufacturing sites in McPherson, Kansas and Rocky Mount, North Carolina — both of which were acquired through the $17 billion Hospira purchase in 2015. The McPherson KS site is the primary US manufacturer of generic injectable opioids (cisplatin, fentanyl, hydromorphone), while Rocky Mount NC focuses on large-volume hospital sterile injectables. Hospira itself was created in 2004 when Abbott Laboratories spun off its hospital products division, separating a $3.5 billion hospital injectable business from Abbott's consumer and diagnostics operations.
Pfizer Inc ↗